Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

Subsequent Events
9 Months Ended
May 31, 2018
Subsequent Events [Text Block]

Subsequent Events


Subsequent to May 31, 2018, the Company issued 747,500 common shares from the exercise of 50,000 warrants at $0.60, 450,000 warrants at $0.14 and 247,500 stock options at $0.091 for a total of $115,500.


On June 28, 2018, the Company announced it filed a new patent application with the United States Patent and Trademark Office for innovation in treatment options related to central nervous system disease or disorders titled: “Enhancement of Delivery of Lipophilic Active Agents Across the Blood- Brain Barrier and Methods for Treating Central Nervous System Disorders” under application number 62689096.


Subsequent to May 31, 2018 the Company is forming new wholly-owned US subsidiary companies. Four new subsidiary companies are being created, one each for the market segments relating to pharmaceutical, hemp, nicotine, and cannabis-related applications.